These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28847987)

  • 1. TRP53 Mutants Drive Neuroendocrine Lung Cancer Through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response.
    Akeno N; Reece AL; Callahan M; Miller AL; Kim RG; He D; Lane A; Moulton JS; Wikenheiser-Brokamp KA
    Mol Cancer Ther; 2017 Dec; 16(12):2913-2926. PubMed ID: 28847987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trp53 null and R270H mutant alleles have comparable effects in regulating invasion, metastasis, and gene expression in mouse colon tumorigenesis.
    Tang J; Feng Y; Kuick R; Green M; Green M; Sakamoto N; Kurosu Y; Lin J; Cho KR; Fearon ER
    Lab Invest; 2019 Oct; 99(10):1454-1469. PubMed ID: 31148594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Establishment of A Patient-derived Xenotransplantation Animal Model for Small Cell Lung Cancer and Drug Resistance Model].
    Zhu Y; Huang W; Wu Y; Jia L; Li Y; Chen R; Guo L; Chen Q
    Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):6-14. PubMed ID: 30674387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential development of large-cell neuroendocrine or small-cell lung carcinoma upon inactivation of 4 tumor suppressor genes.
    Lázaro S; Pérez-Crespo M; Lorz C; Bernardini A; Oteo M; Enguita AB; Romero E; Hernández P; Tomás L; Morcillo MÁ; Paramio JM; Santos M
    Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22300-22306. PubMed ID: 31611390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome.
    Walter RF; Mairinger FD; Werner R; Vollbrecht C; Hager T; Schmid KW; Wohlschlaeger J; Christoph DC
    Oncotarget; 2016 Apr; 7(15):20166-79. PubMed ID: 27064343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation.
    Nakayama M; Sakai E; Echizen K; Yamada Y; Oshima H; Han TS; Ohki R; Fujii S; Ochiai A; Robine S; Voon DC; Tanaka T; Taketo MM; Oshima M
    Oncogene; 2017 Oct; 36(42):5885-5896. PubMed ID: 28628120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific expression of OATPs in primary small cell lung cancer (SCLC) cells as novel biomarkers for diagnosis and therapy.
    Brenner S; Klameth L; Riha J; Schölm M; Hamilton G; Bajna E; Ausch C; Reiner A; Jäger W; Thalhammer T; Buxhofer-Ausch V
    Cancer Lett; 2015 Jan; 356(2 Pt B):517-24. PubMed ID: 25301452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDM2 rs2279744 and TP53 rs1042522 polymorphisms associated with etoposide- and cisplatin-induced grade III/IV neutropenia in Chinese extensive-stage small-cell lung cancer patients.
    Wang X; Wang YZ; Ma KW; Chen X; Li W
    Oncol Res Treat; 2014; 37(4):176-80. PubMed ID: 24732641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report.
    Xie Z; Gu Y; Lin X; Ouyang M; Qin Y; Zhang J; Liu J; Mai S; Zhou C
    Cancer Biol Ther; 2019; 20(9):1172-1175. PubMed ID: 31161851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lineage-restricted neoplasia driven by Myc defaults to small cell lung cancer when combined with loss of p53 and Rb in the airway epithelium.
    Chen J; Guanizo A; Luong Q; Jayasekara WSN; Jayasinghe D; Inampudi C; Szczepny A; Garama DJ; Russell PA; Ganju V; Cain JE; Watkins DN; Gough DJ
    Oncogene; 2022 Jan; 41(1):138-145. PubMed ID: 34675406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of YAP1 defines neuroendocrine differentiation of lung tumors.
    Ito T; Matsubara D; Tanaka I; Makiya K; Tanei ZI; Kumagai Y; Shiu SJ; Nakaoka HJ; Ishikawa S; Isagawa T; Morikawa T; Shinozaki-Ushiku A; Goto Y; Nakano T; Tsuchiya T; Tsubochi H; Komura D; Aburatani H; Dobashi Y; Nakajima J; Endo S; Fukayama M; Sekido Y; Niki T; Murakami Y
    Cancer Sci; 2016 Oct; 107(10):1527-1538. PubMed ID: 27418196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
    Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
    Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Jia D; Augert A; Kim DW; Eastwood E; Wu N; Ibrahim AH; Kim KB; Dunn CT; Pillai SPS; Gazdar AF; Bolouri H; Park KS; MacPherson D
    Cancer Discov; 2018 Nov; 8(11):1422-1437. PubMed ID: 30181244
    [No Abstract]   [Full Text] [Related]  

  • 14. Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer.
    Cai L; Liu H; Huang F; Fujimoto J; Girard L; Chen J; Li Y; Zhang YA; Deb D; Stastny V; Pozo K; Kuo CS; Jia G; Yang C; Zou W; Alomar A; Huffman K; Papari-Zareei M; Yang L; Drapkin B; Akbay EA; Shames DS; Wistuba II; Wang T; Johnson JE; Xiao G; DeBerardinis RJ; Minna JD; Xie Y; Gazdar AF
    Commun Biol; 2021 Mar; 4(1):314. PubMed ID: 33750914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.
    Mollaoglu G; Guthrie MR; Böhm S; Brägelmann J; Can I; Ballieu PM; Marx A; George J; Heinen C; Chalishazar MD; Cheng H; Ireland AS; Denning KE; Mukhopadhyay A; Vahrenkamp JM; Berrett KC; Mosbruger TL; Wang J; Kohan JL; Salama ME; Witt BL; Peifer M; Thomas RK; Gertz J; Johnson JE; Gazdar AF; Wechsler-Reya RJ; Sos ML; Oliver TG
    Cancer Cell; 2017 Feb; 31(2):270-285. PubMed ID: 28089889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung.
    Balasubramaniam S; Redon CE; Peer CJ; Bryla C; Lee MJ; Trepel JB; Tomita Y; Rajan A; Giaccone G; Bonner WM; Figg WD; Fojo T; Piekarz RL; Bates SE
    Anticancer Drugs; 2018 Jun; 29(5):457-465. PubMed ID: 29420340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific statin sensitivity.
    Turrell FK; Kerr EM; Gao M; Thorpe H; Doherty GJ; Cridge J; Shorthouse D; Speed A; Samarajiwa S; Hall BA; Griffiths M; Martins CP
    Genes Dev; 2017 Jul; 31(13):1339-1353. PubMed ID: 28790158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy.
    Hubaux R; Vandermeers F; Crisanti MC; Kapoor V; Burny A; Mascaux C; Albelda SM; Willems L
    Eur J Cancer; 2010 Jun; 46(9):1724-34. PubMed ID: 20451370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.
    Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H
    Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A crucial requirement for Hedgehog signaling in small cell lung cancer.
    Park KS; Martelotto LG; Peifer M; Sos ML; Karnezis AN; Mahjoub MR; Bernard K; Conklin JF; Szczepny A; Yuan J; Guo R; Ospina B; Falzon J; Bennett S; Brown TJ; Markovic A; Devereux WL; Ocasio CA; Chen JK; Stearns T; Thomas RK; Dorsch M; Buonamici S; Watkins DN; Peacock CD; Sage J
    Nat Med; 2011 Oct; 17(11):1504-8. PubMed ID: 21983857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.